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Background: There is a need for an instrument to measure the psychosocial burden of receiving an abnormal
cervical cytology result which can be used regardless of the clinical management women receive.
Methods: 3331 women completed the POSM as part of baseline psychosocial assessment in a trial of management of
low grade cervical cytological abnormalities. Factor analysis and reliability assessment of the POSM were conducted.
Results: Two factors were extracted from the POSM: Factor 1, containing items related to worry; and Factor 2
containing items relating to satisfaction with information and support received and change in the way women felt
about themselves. Factor 1 had good reliability (Cronbach’s alpha 0.769), however reliability of the Factor 2 was poorer
(0.482). Data collected at four subsequent time points demonstrated that the factor structure was stable over time.
Conclusion: This study demonstrates the presence and reliability of a scale measuring worries within the POSM. This
analysis will inform its future use in this population and in other related contexts.
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Almost 4 million cervical cytology tests are undertaken
every year in the UK, and over 6% of these are reported
as abnormal [1,2]. The majority of these are reported as
showing low-grade abnormalities, i.e. borderline nuclear
changes (BNC) or mild dyskaryosis.
It has been well established that receipt of an abnormal
cervical cytology result can cause significant negative psy-
chological consequences [3-12]. The adverse psychosocial
sequelae relating to receipt of abnormal results and subse-
quent management represent the psychological cost of
cervical screening. Several of these studies have investi-
gated the effects of receiving an abnormal result on anx-
iety and depression. However, cervical screening may raise
a range of other psychosocial issues for women, including* Correspondence: s.c.cotton@abdn.ac.uk
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unless otherwise stated.worries about their health, sexual functioning, future fer-
tility and the development of cervical cancer [13].
At least two measures [14-16] have been developed for
assessing the burden of psychosocial sequelae in women
with abnormal cervical cytology. However, these may
have limited applicability because they include questions
relating to distress specifically due to colposcopy or gy-
naecological examination, which may not be relevant to
women managed in other ways, for example, by cyto-
logical surveillance.
The existence of an appropriate instrument to measure
psychosocial burden in women with low-grade abnor-
malities (irrespective of the way in which they are man-
aged) would allow a better estimation of the magnitude
of the problem; facilitate comparison of the psychosocial
burden associated with different managements strategies;
and enable the evaluation of any interventions designed to
reduce the psychosocial burden of receiving an abnormal
cervical cytology result or management thereof.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the TOMBOLA (Trial Of Management of Borderline
and Other Low-grade Abnormalities) trial was a rando-
mised controlled trial (RCT) which aimed to clarify the
most effective and cost-effective management strategy
for women with low-grade abnormal cervical cytology
[17]. One component of the trial was the comparison of
the psychosocial burden between women in the different
management arms, immediate colposcopy versus cyto-
logical surveillance.
A number of previously validated questionnaires, includ-
ing the Hospital Anxiety and Depression Scale (HADS)
[18] and the EuroQoL EQ-5D-3 L [19], were used in
TOMBOLA to measure women’s responses to having re-
ceived a low-grade abnormal cervical cytology result and
their subsequent management. However, no existing ques-
tionnaire could be identified to assess adequately the full
spectrum of potential psychosocial consequences or one
which was applicable to women managed in different ways.
The Process and Outcome Specific Measure (POSM)
was therefore developed within TOMBOLA, to address
this gap [20]. The POSM is a short, easy-to-use, 14 item
questionnaire which can assess the psychosocial impact
of receiving an abnormal cytology result and the impact
of different management strategies. The POSM was spe-
cifically designed to capture aspects of women’s responses
to an abnormal cytology result that would be sensitive to
different processes of management. Although not origin-
ally designed to be reported as a single score, or a series of
sub-scores, early pilot work [20] based on a small number
of participants suggested that the POSM may have a suit-
able level of reliability to be reported as a scale.
This paper reports the results of an exploratory factor
analysis and reliability analysis of the POSM questions
utilising the full trial dataset, which included 3331 women.
We aimed to explore possible latent factors in the pool of
POSM questions and reliability of these factors in order to
better inform future use and reporting of the POSM
questions.
Methods
The TOMBOLA trial and participants
The TOMBOLA trial design has been described in detail
elsewhere [17]. Briefly, eligible women were aged 20–59
years, had received a low-grade abnormal cervical cytology
result (BNC or mild dyskaryosis) between October 1999
and October 2002 from a routine cervical screening test
taken as part of the NHS Cervical Screening Programmes,
lived in the Grampian or Tayside areas of Scotland or the
Nottingham area of England, and had not had more than
one additional BNC result in the previous three years.
Women were not eligible if they had previous treatment
for proven or suspected cervical lesions, or were pregnant
at the time of recruitment. Eligible women were sent aninformation leaflet and a letter inviting them to a recruit-
ment clinic, and were recruited on average 8 weeks after
having the abnormal test. All women recruited from
February 2001 onwards were included in the psycho-
social component of the trial, and therefore eligible for
this analysis.
Measures
At the recruitment clinic, and after giving informed con-
sent, women completed a socio-demographic and lifestyle
questionnaire, and baseline psychosocial questionnaire.
The psychosocial questionnaire included the POSM, the
HADS and the EuroQoL EQ-5D-3 L.
The 14-items of the POSM related to: feeling well
enough informed about the abnormal result; information
received having addressed concerns; worries about health,
cancer, next test showing changes, having sex and future
fertility; delaying pregnancy; changes to feelings about self
and to sex life; satisfaction with support, beliefs about cer-
vical screening, future screening intentions, and perceived
risk of developing cervical cancer. Each question had be-
tween five and seven response options on a Likert scale.
Responses ranged from “Strongly agree” to “Strongly dis-
agree” for most questions; from “Strongly for the better”
to “Strongly for the worse” for the two questions relating
to change; and from “Very much lower than average” to
“Very much higher than average” for the perceived risk
question. In addition, there were two filter questions relat-
ing to intention to have children and sexual activity, which
allow women to skip questions which are not relevant to
them. A copy of the POSM questions is included as an
additional file (Additional file 1).
We developed two slightly different versions of the
POSM. In the version administered at the recruitment
clinic, the questions were framed to refer to the period
between receiving the abnormal result and completing
the questionnaire. The alternative version was developed
for administration during follow-up and women received
it by post at 12, 18, 24 and 30 months after recruitment.
In this version the time frame for each question referred
to the previous month and the question relating to the
extent to which information received having addressed
concerns women had about their smear result since the
abnormal cytology result was omitted.
The HADS, was originally developed to screen for
clinically significant levels of anxiety and depression in a
medical outpatient setting, but has since been found to
have acceptable reliability for use in primary care [21].
The HADS is a self reported questionnaire which consists
of 14 items on two sub-scales, with seven measuring anx-
iety and seven measuring depression. Items are scored on
a four point scale from 0 to 3, to yield a score out of 21
for each sub-scale. Scores are generally used to categorise
subjects on each sub-scale into non-cases (0–7), possible
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refer to the previous week.
The EuroQoL EQ-5D-3 L [19] is a widely used generic
measure of health related quality of life. This analysis
uses the EQ-5D visual analogue scale (VAS), which con-
sists of a 20 cm scale numbered 0–100. Respondents are
asked to mark on the scale how they rate their health
that day.Selection of questions for factor analysis
An initial review of the questions included in the POSM
was undertaken in order to select a pool of questions
which would be applicable to all participants and all ver-
sions of the POSM. To this end, some questions were
deleted from the item pool before factor analysis.
One question (‘The information I have received has
answered the concerns I have had about my smear re-
sult’) was not considered for inclusion in the factor ana-
lysis since it was only included in the version of the
POSM used at baseline, and not included in the follow-
up questionnaire.
Items were assessed on their face validity, i.e. to the
extent to which they were related to the psychosocial
burden of receiving an abnormal cervical cytology result.
After discussion within the research team, it was decided
that all but three items were related to psychosocial bur-
den. The three items which were not related to psycho-
social burden were deleted from the item pool and not
considered for this analysis. These items were: “What do
you feel your chances of getting cervical cancer are com-
pared to other women”, “I believe that having regular
smears reduces my risk of getting cervical cancer “and “I
intend to continue having regular smears”.
Three of the remaining questions were only answered
by particular groups of women. Two of these questions
were only answered by women who were sexually active
at the time of completing the questionnaire and one of
these only by women intending to have children in the
future. These three questions were also deleted from the
item pool and not considered for factor analysis. This left
7 questions, henceforth referred to as “core” questions.Factor and reliability analysis
The initial analysis included data from 3331 women who
completed the baseline POSM at recruitment. We con-
ducted exploratory factor analysis on the core questions
in order to identify any scales within the POSM question-
naire. We made no prior assumptions about any possible
factor structure.
An inter-item correlation matrix of responses to the
core POSM questions was prepared. Items were assessed
for inclusion in the factor analysis on the basis of suffi-
cient correlation (r > 0.2) with at least one other item.The Kaiser-Meyer-Olkin (KMO) test and Bartlett’s
test of sphericity were conducted to test whether there
was sufficient common variance and correlation be-
tween core questions to carry out principal components
analysis. According to convention [22], a minimum level
of 0.5 was used for the KMO test to indicate sufficient
common variance.
Both Cattell’s Scree plot method [22] and Kaiser’s criter-
ion (retention of factors with eigenvalues greater than
one) [23] were used to determine the number of factors to
extract. Factors were then extracted using principal com-
ponents analysis and rotated with varimax rotation [24].
The internal consistency reliability of the resultant
factors was assessed using Cronbach’s alpha (Cα). Item-
total correlations were calculated in order to assess
whether the items within each factor behaved consist-
ently. Following standard practice [25], a correlation of
over 0.2 was considered acceptable. Spearman’s correl-
ation coefficient was calculated between items and each
of the factors. We calculated corrected item-total corre-
lations by calculating correlations between items and
total scores for each factor excluding that item. We
assessed discriminant validity by correlating individual
items with the EQ-5D visual analogue scale (VAS) and
the anxiety and depression sub-scales of the HADS. We
assessed whether the POSM measured something dis-
tinct from health-related quality of life and anxiety and
depression by correlating the factor scores with the
HADS and EQ-5D VAS scores: in this event, it would be
expected that items from the POSM would correlate more
strongly with factor scores that they belong to than with
the EQ-5D VAS score or the HADS sub-scale scores.
Scoring
A scoring scheme was devised for the core questions such
that a high score indicated greater psychosocial burden.
Since the number of response options differed between the
POSM items, scores were standardised. For each question,
response categories were given a raw score, ranging from 1
to 6 (1 to 7 for the single question which had a central neu-
tral response option). The raw score for each question was
multiplied by 100 and divided by the maximum possible
raw score for that question. Item responses for each ques-
tion were thus standardised to be scored out of 100.
In order to obtain factor scores, standardised scores
for the questions included in that factor were summed
and divided by the number of items within the factor.
Thus, scores for each of the factors were out of 100. To
have a score for a factor, women had to answer all ques-
tions which form that factor.
Sensitivity analysis
In order to assess the effect of excluding items which
were judged to have low face validity, we performed a
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cluding these items. Reliability analysis was then repeated.
A series of further factor analyses were performed using
data from the questionnaires completed by women at 12
(n = 2181), 18 (n = 1993), 24 (n = 1880) and 30 (n = 1737)
months post-recruitment. These analyses were then re-
peated at each time point for each trial arm separately.
The results of these analyses were compared to that from
the analysis of the baseline dataset to assess the temporal
stability of the factor structure.
Since the POSM has been used as single scale in the
past [20], we assessed the reliability of including the
items in one score. We used the core questions, as these
questions were relevant to all women and all versions of
the POSM, and also all related to psychosocial burden.
We constructed an “overall score” out of 100 in a similar
way to the factor scores. We then calculated corrected
item total correlations and Cronbach’s alpha in the same
way as before.
Details of ethical approval
Ethical approval was obtained from the Joint Research
Ethics Committee of NHS Grampian and the University
of Aberdeen (Reference 970072), the Tayside Committee
on Medical Research Ethics (170/99) and the Nottingham
Research Ethics Committee (PA129701).
Results
Characteristics of participants
The sociodemographic characteristics of the 3331 women
and included in the factor analysis of baseline data are
shown in Table 1.
Responses
The responses to the POSM questions are summarised
in Additional file 1. In general, the level of missing re-
sponses was low. The exception to this was 14.8% for
the question “since receiving my smear result my sex life
has changed”. Five of the items showed significant clus-
tering of responses on single response options, including
four which had been removed from the main pool of
questions for this analysis: “I intend to continue having
regular smears”; “I believe that having regular smears re-
duces my risk of getting cervical cancer”; “What do you
feel your chances of getting cervical cancer are com-
pared to other women”; and “Since getting my smear re-
sult my sex life has changed”. One was from the pool of
remaining questions: “Since getting my smear result the
way I feel about myself has changed”.
Factor structure – baseline data
The Kaiser-Meyer-Olkin (KMO) measure for the core
questions was 0.74, and Bartlett’s test of sphericity (p <0.001) indicated that common variance between items was
sufficient to carry out a principal components analysis.
Factor analysis
Kaiser’s criterion and Cattel’s scree plot both suggested
the extraction of two factors. The rotated factor struc-
ture of these factors is displayed in Table 2; values
under 0.4 have been suppressed for clarity. The two ex-
tracted factors explained 54.7% of the variance from the
original data.
All of the items loaded onto a factor, and none of the
items loaded onto more than one factor. The items that
were associated with each other suggested that the first
factor represented worries (hereafter referred to as the
Worry factor) and the second factor represented infor-
mation and support (henceforth Information-Support
factor). In addition to questions about feeling well enough
informed and being satisfied with support from other
people, this second factor also included the question on
changes in how women felt about themselves. The low
loading of this latter question (0.445) indicates that, al-
though it fits better in this factor than elsewhere, its as-
sociation with this factor is less strong than the other
two questions.
Reliability
Corrected item-total correlations are shown in Table 3.
The item-total correlations between constituent items
and the Worry score were moderate to high (between
0.405 and 0.659). The item-total correlation for two of
the Information-Support score questions (“In general I
feel well enough informed about what my smear result
means” and “Since getting my smear result I have gener-
ally been satisfied with the support I have had from other
people”) was moderate. However the item total correlation
for the other question (“Since getting my smear result the
way I feel about myself has changed”) was low.
The Worry factor had good reliability (Cα = 0.769). The
reliability of the Information-Support factor was poorer
(Cα = 0.430). Removal of the question relating to changes
in the way women felt about themselves, increased reli-
ability slightly (Cα = 0.482).
Table 4 shows the correlations between the Worry and
Information-Support factors, the overall score and the
HADS and EQ-5D VAS scores. These results indicate
that there is some overlap between the Worry factor and
HADS anxiety. However, the correlations between the
factor scores and the HADS depression score, and EQ-
5D VAS scores were lower.
Sensitivity analysis
Cronbach’s alpha for the overall score for the core ques-
tions was 0.668, slightly less than the acceptable level.
Most of the correlations between individual questions
Table 1 Sociodemographic characteristics of women
included in this study
Characteristic N %
Age group (n = 3331)
20-29 1440 43.2
30-39 887 26.6
40-49 708 21.3
50-59 296 8.9
Ethnic group (N = 3318; missing = 13)
White 3180 95.8
Non-white 138 4.2
Trial centre (N = 3331)
1 1068 32.1
2 834 25.0
3 1429 42.9
Employment status (N = 3323; missing = 8)
Full-time paid employment 1663 50.0
Part-time paid employment 771 23.2
Student 307 9.2
Not in paid employment 582 17.5
Carstairs quintile (N = 3331)
1 (Least deprived) 469 14.1
2 623 18.7
3 533 16.0
4 877 26.3
5 (Most deprived) 829 24.9
Marital status (N = 3298; missing = 33)
Married or cohabiting 1829 55.5
Divorced, separated or widowed 445 13.5
Single 1024 31.0
Reproductive history (N = 3297; missing = 34)
Never pregnant 1119 33.9
Ever pregnant 2178 66.1
Cervical screening history (N = 3331)
No previous borderline nuclear changes 3022 90.7
Previous borderline nuclear changes 309 9.3
Recruitment cytology test result (N = 3331)
Mild dyskaryosis 892 26.8
Borderline nuclear changes 2439 73.2
Post school education and training
(N = 3319; missing = 12)
None 885 26.7
Qualification through work 660 19.9
Qualification other than degree from
college/university
953 28.7
Degree from college/university 821 24.7
Table 1 Sociodemographic characteristics of women
included in this study (Continued)
Currently using oral contraceptive (N = 3325;
missing = 6)
No 2182 65.6
Yes 1143 34.4
Physical activity outside work (N = 3291;
missing = 40)
<Once per week 1298 39.4
1-3 times per week 781 23.7
>3 times per week 1212 36.8
Smoking status (N = 3302; missing = 29)
Never Smoker 1575 47.7
Ex-smoker 567 17.2
Current Smoker 1160 35.1
Rothnie et al. Health and Quality of Life Outcomes 2014, 12:154 Page 5 of 9
http://www.hqlo.com/content/12/1/154and the overall score were acceptable (0.205-0.587).
However two questions had correlations of less than 0.2;
these related to changes in the way women felt about
themselves, and satisfaction with support from other
people. One question, changes in the way women felt
about themselves, correlated more highly with the HADS
anxiety subscale than with the overall score. Correlations
between the overall score and the HADS and EQ-5D VAS
scores followed a similar pattern to the Worry factor
(Table 4).Table 2 Factor structure of the core POSM questions
POSM question Worry factor Information-Support
factor
Since getting my smear result I
have been worried that I may
have cervical cancer.
0.846
Since getting my smear result I
have been worried about my
general health.
0.819
Since getting my smear result I
have been worried that my
next smear will show changes
to the cells.
0.814
Since getting my smear result I
have been worried about
having sex.
0.581
In general I feel well enough
informed about what my
smear result means.
0.778
Since getting my smear result I
have been satisfied with the
support I have had from other
people.
0.767
Since getting my smear result
the way I feel about myself has
changed.
0.445
Factor loadings under 0.4 have been suppressed for clarity.
Table 3 POSM item-total correlations and correlations with the HADS scales and the EQ-5D VAS
POSM question (Abbreviated) Worry factor Information-Support
factor
Overall score HADS anxiety HADS
depression
EQ-5D VAS
Worried that I may have cervical cancer 0.659 0.101 0.587 0.410 0.254 −0.131
Worried about general health 0.636 0.061 0.560 0.412 0.278 −0.198
Worried next smear will show changes to
the cells
0.618 0.081 0.550 0.382 0.200 −0.132
Worried about having sex 0.405 0.083 0.385 0.311 0.236 −0.142
Well enough informed about what smear
result means
0.122 0.326* 0.205 0.109 0.087 −0.072
Satisfied with support from other people 0.049 0.298* 0.147 0.085 0.124 −0.086
Way I feel about myself has changed 0.238 0.161 0.187 0.196 0.149 −0.075
Items which form a part of these scores are indicated in bold and are corrected item-total correlations.
*0.319 when item “way I feel about myself has changed” is removed from Information-Support factor score.
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moved because of low face validity, the previous two fac-
tors (Worry and Information-Support) did not change.
One of the new questions “What do you feel your chances
of getting cervical cancer are compared to other women”
did not load onto any factor. The other two questions “I
intend to continue having regular smears” and “I believe
that having regular smears reduces my risk of getting can-
cer” both loaded onto a new, third factor. This factor had
very low reliability (Cα = 0.217).
Analysis of data collected at 12, 18, 24 and 30 months
post-recruitment indicated that both the Worry and
Information-support factors were stable over time, and
that there was no difference in factor structure between
trial arms, i.e. the same questions loaded onto the same
factors (data not shown).
Discussion
Summary of results
Psychosocial sequelae are an important consequence of
both the receipt of an abnormal cervical cytology result
and the subsequent management of the abnormality
[13]. The POSM was developed to measure these psy-
chosocial sequelae.
We investigated a pool of POSM questions to identify
possible latent factors, and assessed the ability of these
factors to act as scales. Factor analysis revealed that that
there were two latent factors. These related to: (1) Worry
(four questions) and (2) Satisfaction with information and
support (three questions).Table 4 Correlations between the POSM scores and the
HADS and EQ-5D VAS scores
HADS anxiety HADS depression EQ-5D VAS
Worry 0.487 0.316 −0.192
Information-Support 0.145 0.140 −0.111
Overall score 0.486 0.330 −0.200We removed some questions from the pool of POSM
questions to be entered into the factor analysis. Three of
the questions were removed as it was felt that they did
not relate to psychosocial distress. This decision was
borne out in the sensitivity analysis which showed that
these items, when added to the factor analysis, did not
change the structure of the initial two factors, and also
did not form a factor with appreciable reliability. In
addition, all three of these items were among the five
items which showed significant clustering of responses.
We also removed three questions from the pool because
they were only answered by some women. This decision
was driven by the desire to explore the possibility of
finding a useful summary score, or scores, within the
POSM items which would be relevant to all women the
POSM was administered to.
The reliability of the Worry factor was supported by
reliability assessment. However, the reliability measures
for the Information-Support factor were somewhat lower,
but considering the small number of items in this factor
(n = 3) this was not surprising. In the additional analysis,
the reliability of the overall score based on the core
questions fell just below the pre-defined acceptable level
of reliability.
The discriminant validity of the POSM scores was dem-
onstrated by the correlations between factor scores and
the overall score and the EQ-5D VAS and HADS scores.
These results indicated that, in general, the POSM core
questions measured constructs which were distinct from
anxiety and depression (as measured by the HADS) and
self-perceived health-related quality of life (as measured
by the EQ-5D VAS). Thus, the POSM achieved its aim in
measuring the psychosocial consequences of receiving an
abnormal cytology result, and the management thereof,
beyond that measured by existing questionnaires.
These results also indicate that higher scores (more
distress) on the scales assessed here were associated with
lower health-related quality of life (lower EQ-5D VAS
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lated to HADS measured anxiety, and to a lesser extent,
HADS measured depression. The correlations between
the overall score and the other measures followed a simi-
lar pattern to the Worry factor score. This was not sur-
prising as these two scores differed only by three items.
The temporal stability of the POSM factor structure
was confirmed by further factor analysis of responses to
the POSM using 12, 18, 24 and 30 month follow up
datasets from the TOMBOLA trial.
Scoring the POSM
The method used here for scoring the POSM differs
slightly from the method used during the original pilot
study [20]. The method presented here is based on the
results of the factor analysis, analysis of a larger dataset
and further thinking about how the POSM could be
used in other populations. Standardising the scores for
individual questions, and in the summing of these, al-
lows one to compare total scores for women who may
have completed different numbers of the core questions.
This is useful since, as with all questionnaires, a small
number of respondents may not chose to answer all in-
dividual questions.
Strengths and weaknesses
One potential weakness of this study is the age of the data,
which were collected between 1999 and 2003 for the base-
line analysis. However, we have no reason to believe that
psychosocial distress relating to cervical screening has
changed in such a way as to impact on the psychometric
properties of this instrument. Also, the data used in this
study were obtained from women who had consented to
take part in an RCT and, as a result, may have differed
from women in the general screening population. How-
ever, the sample used for both the original POSM devel-
opment and the analysis presented in this paper was
drawn from the UK cervical screening population and the
trial design was population-based (i.e. all eligible women
in the relevant areas were invited to participate). This is a
strength compared to other questionnaires [15], which
have used sampling strategies which over-represented
some groups used to generate and validate questionnaire
items. This study also benefits from a large sample size,
which was in excess of 3300 women. A further advantage
of the POSM is that it is not management-specific, that is,
it does not contain items which are only relevant to
women who had received a particular intervention as a
result of their abnormal cervical cytology; this is in con-
trast to other similar measures [14-16]. Furthermore, the
POSM has been designed such that it measures the psy-
chosocial burden of both initial receipt of an abnormal
cytology result and its subsequent follow up. In practice,
this means that the POSM may be used to compare thepsychosocial effects of receiving an abnormal cervical
cytology result between women who subsequently under-
went different clinical follow-up. It is interesting, but per-
haps unsurprising, that the Worry factor extracted from
the POSM incorporates some similar questions to those
included in the “worries and concerns” scale of the HPV
Impact Profile, for example about abnormal smear test re-
sults and cervical cancer [16].
Future use of the POSM
Although the POSM was developed for use in women
who have received a low-grade abnormal cytology result
in the context of the UK screening population, it has the
potential to be used in other populations, such as in
women with higher grade cytology or with precancerous
or cancerous lesions, and those with other gynaecological
disorders. Indeed, the POSM has recently been used in
women with microinvasive cancer of the cervix [26], in
women who have been referred for colposcopy after either
a low or high-grade abnormal cytology result [27] and in
women with vulval intraepithelial neoplasia [28].
Cervical screening and management are changing, with
an increasing focus on testing for infection with high-risk
types of human papillomavirus (HPV). The nature of the
questions in the POSM suggests that there is no impedi-
ment to its use in women who have had HPV tests in
addition to, or instead of, cytology tests. For example,
following the introduction of HPV triage in the NHS in
England [29], there may be scope for using the POSM in
measuring the psychosocial effects of a positive HPV test.
Alternatively, following the adoption of cytology and HPV
co-testing for primary screening in the USA [30,31] and
in the Netherlands [32], it may be possible to use the
POSM to compare the psychosocial impact of a positive
HPV test (and negative cytology test), an abnormal cy-
tology test (and negative HPV test), or positive cytology
and HPV tests.
For future use of the POSM, we recommend that the
pool of seven core questions tested here be administered
to all women. These questions are relevant to all women.
The use of the three supplementary questions (those re-
lating to women who are sexually active and/or planning
on having children) will depend on their relevance to
the research question and the sociodemographic charac-
teristics of the study population. The same applies to the
remaining questions (those which were qualitatively differ-
ent from the core and supplementary questions because
they concerned perceptions of risk and intended behav-
iour). In reporting the POSM, researchers may choose to
report women’s responses to individual questions (if, for
example, specific issues such as worries about cervical
cancer are of particular interest). As this analysis suggests,
responses to the four relevant questions which are part of
the worry factor may be reported as a worry score in
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ual items which do not form the worry factor. Alterna-
tively, researchers may, for pragmatic reasons, wish to
report an overall score for the seven questions relevant to
all women. The psychometric properties of this overall
score are reported here for guidance.
Conclusions
This study has demonstrated two latent factors in a sub-
set of POSM questions relating to psychosocial burden.
Reliability analysis has shown that one of these factors
has suitable psychometric properties to be used as a scale
to measure worries related to cervical screening. This ana-
lysis will inform its future use in this population and in
other related contexts.
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